SIKs suppress tumor function and regulate drug resistance in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Salt-inducible kinases (SIKs), part of the AMP-activated kinase (AMPK) family, are implicated in various solid tumors.
• The specific roles of SIK family members in breast cancer remain incompletely understood.

Purpose of the Study:

• To systematically investigate the functions of SIK1, SIK2, and SIK3 in breast cancer.
• To determine the association between SIK expression and clinical outcomes in breast cancer patients.

Main Methods:

• Analysis of SIK expression in a clinical breast cancer cohort.
• In vitro studies using breast cancer cell lines to assess the impact of SIK knockdown on proliferation, adhesion, and invasion.
• Evaluation of chemoresistance following SIK knockdown.

Main Results:

• Increased expression of SIK1, SIK2, and SIK3 was linked to favorable clinical outcomes.
• SIK2 and SIK3 knockdown enhanced breast cancer cell proliferation.
• SIK2 and SIK3 exhibited differential effects on cell adhesion, with SIK2 knockdown increasing adhesion in triple-negative cells and SIK3 knockdown decreasing it in MDA-MB-231 and MCF-7 cells.
• SIK1 and SIK3 knockdown promoted invasion in MDA-MB-231 cells.
• Reduced SIK expression, including triple knockdown, conferred resistance to paclitaxel and cisplatin.

Conclusions:

• SIKs play a significant role in regulating aggressive behaviors of breast cancer cells.
• SIKs are potential prognostic factors and biomarkers for chemotherapy response in breast cancer.